Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.

Proceedings of the National Academy of Sciences of the United States of America - 8 Jul 2014

Mellios Nikolaos, Woodson Jonathan, Garcia Rodrigo I, Crawford Benjamin, Sharma Jitendra, Sheridan Steven D, Haggarty Stephen J, Sur Mriganka

Abstract excerpt

Rett syndrome is a severe childhood onset neurodevelopmental disorder caused by mutations in methyl-CpG-binding protein 2 (MECP2), with known disturbances in catecholamine synthesis. Here, we show that treatment with the β2-adrenergic receptor agonist clenbuterol increases survival, rescues abnormalities in respiratory function and social recognition, and improves motor coordination in young male Mecp2-null...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Behavior, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Insulin-Like Growth Factor I

Share to Methyl-CpG-Binding Protein 2

Share to Mice, Mutant Strains

Share to MicroRNAs

Share to Receptors, Adrenergic, beta-2

Share to Rett Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 24958851
DOI: 10.1073/pnas.1309426111
PMCID: PMC4103343

Genes

IGF1
MECP2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.PMID 24958851Read ↗

Rett syndrome treatment in mouse models: searching for effective targets and strategies.Semantic proximity Read ↗

Leptin antagonism improves Rett syndrome phenotype in symptomatic Mecp2-deficient mice.Semantic proximity Read ↗

Affective dysfunction in a mouse model of Rett syndrome: Therapeutic effects of environmental stimulation and physical activity.Semantic proximity Read ↗

Autonomic dysfunction with mutations in the gene that encodes methyl-CpG-binding protein 2: insights into Rett syndrome.Semantic proximity Read ↗

5-HT1A Receptor Agonist Treatment Partially Ameliorates Rett Syndrome Phenotypes in mecp2-Null Mice by Rescuing Impairment of Neuron Transmission and the CREB/BDNF Signaling Pathway.Semantic proximity Read ↗

Breathing dysfunction in Rett syndrome: understanding epigenetic regulation of the respiratory network.Semantic proximity Read ↗

Leptin antagonism improves Rett syndrome phenotype in symptomatic <i>Mecp2-</i> deficient miceSemantic proximity Read ↗

Selective preservation of cholinergic MeCP2 rescues specific Rett-syndrome-like phenotypes in MeCP2stop mice.Semantic proximity Read ↗

Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives.Semantic proximity Read ↗

Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor.Semantic proximity Read ↗

MeCP2 dysfunction in humans and mice.Semantic proximity Read ↗

Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.